The company attributed lower revenues to the negative impact from the COVID-19 pandemic but highlighted its ongoing R&D efforts to expand the drug's indication.
Schrödinger will be eligible to receive $338 million in milestone payments if the DNA damage candidate is commercialized.
The firm will open cancer-specific cohorts of HR-positive breast cancer and KRAS-mutated NSCLC patients as a next step in its ongoing Phase I/II clinical trial.
The Phase I dose escalation and dose expansion study is enrolling up to 76 patients with PSMA-expressing solid tumors.
The partners will explore the activity of mirdametinib with fulvestrant in breast cancer patients with MAPK alterations and as a single agent in other MAPK-altered solid tumors.
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
The firm will begin enrolling MAGE-A1-positive solid cancer patients to a Phase I/II clinical trial of its autologous TCR therapy TK-8001 later this year.
Researchers at the university will use Avalon's FLASH-CAR technology to speed up the development of treatments and improve their efficacy against cancer cells.
The Phase Ib/II trial will evaluate Carrick's CDK7 inhibitor samuraciclib and Roche's giredestrant in HR-positive, HER2-negative metastatic breast cancer.
The company said it planned to use the funds for the development of a liquid biopsy assay for predicting patient response to immune checkpoint inhibitors.